Compare APWC & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APWC | VERU |
|---|---|---|
| Founded | 1996 | 1971 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.1M | 39.8M |
| IPO Year | 1997 | 1990 |
| Metric | APWC | VERU |
|---|---|---|
| Price | $1.86 | $2.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 17.2K | ★ 109.7K |
| Earning Date | 08-14-2025 | 12-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $492,001,000.00 | $16,886,419.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.28 | ★ N/A |
| Revenue Growth | 5.10 | ★ 337.24 |
| 52 Week Low | $1.36 | $2.11 |
| 52 Week High | $2.34 | $14.20 |
| Indicator | APWC | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 40.04 |
| Support Level | $1.74 | $2.33 |
| Resistance Level | $1.89 | $2.63 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 74.99 | 40.41 |
Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, PRC, Hong Kong and certain other markets in the Asia Pacific region. It also provides project engineering services in the supply, delivery and installation of power cables (SDI). Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and Rest of the World.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.